Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer put under the microscope. Cramer recalled his discussion with the company’s CEO, and commented: “What else might work? Last Friday on the show, we had Joaquin Duato. He’s the CEO of Johnson & Johnson, and he told a remarkable story about game-changing cancer drugs and medical devices, especially their excellent cardio products. Now, I’ve been worried about the talc lawsuits that they have, but I believe the risk from the asbestos and the baby po ...

公司评级与目标价 - Truist证券首次覆盖Janux Therapeutics并给予买入评级 目标价100美元 [2] - 看好公司作为癌症药物开发商的未来发展前景 [2] 公司催化剂事件 - 2024年下半年公司将进入催化剂密集期 [2] - 多项重要研发进展预计将在未来数月内公布 [2]